Cobenfy (KarXT) commercially available in the U.S. by December 31, 2024? | Binary | | | 3 months ago | |
Cobenfy (KarXT) approved by the EMA by June 30, 2025? | Binary | | | 3 months ago | |
Will KarXT (Cobenfy) receive EMA approval by September 26, 2025? | Binary | | | 3 months ago | |
Which company will have better stock performance by end of 2024: AbbVie or Bristol Myers? | Categorical | | | 1 month ago | |
Will Bristol Myers Squibb's Cobenfy receive additional FDA approval by June 30, 2025? | Binary | | | 1 month ago | |
Will AbbVie's stock recover to pre-trial levels by March 31, 2025? | Binary | | | 1 month ago | |
What will be Cobenfy's market share among schizophrenia treatments by the end of 2025? | Categorical | | | 3 months ago | |
Will Cobenfy achieve $1 billion in sales by the end of 2025? | Binary | | | 3 months ago | |
Will Bristol Myers Squibb's stock price increase by more than 10% by the end of 2024? | Binary | | | 3 months ago | |
Will Cobenfy receive a black box warning from the FDA by the end of 2025? | Binary | | | 3 months ago | |
How many new schizophrenia drugs will FDA approve by end of 2025? | Categorical | | | 3 months ago | |
Will Cobenfy reach $1 billion in sales by the end of 2025? | Binary | | | 3 months ago | |
What will Cobenfy's market share among schizophrenia treatments be by end of 2025? | Categorical | | | 3 months ago | |
Will Cobenfy achieve FDA fast-track designation for another indication by end of 2024? | Binary | | | 3 months ago | |
Cobenfy (KarXT) generate over $1 billion in sales by the end of 2025? | Binary | | | 3 months ago | |
Will KarXT (Cobenfy) become the leading schizophrenia treatment in the U.S. by prescription volume by September 26, 2025? | Binary | | | 3 months ago | |
How many new muscarinic receptor-targeting drugs will be FDA approved by end of 2025? | Categorical | | | 29 days ago | |
Will KarXT receive FDA approval for Alzheimer's treatment by end of 2025? | Binary | | | 29 days ago | |
Will KarXT be included in APA guidelines for schizophrenia by end of 2025? | Binary | | | 29 days ago | |
Will a major pharmaceutical company acquire marketing rights for KarXT by end of 2025? | Binary | | | 29 days ago | |
What will be KarXT's market penetration for schizophrenia by end of 2025? | Categorical | | | 29 days ago | |
What will be KarXT's impact on cognitive function in Alzheimer's by end of 2025? | Categorical | | | 29 days ago | |
Which company will receive the next major FDA approval for schizophrenia treatment by end of 2025? | Categorical | | | 1 month ago | |
What will be AbbVie's next major strategic move by June 30, 2025? | Categorical | | | 1 month ago | |
Will AbbVie announce new clinical trial results for Emraclidine by end of 2024? | Binary | | | 1 month ago | |
What will be the peak annual sales of Cobenfy by the end of 2025? | Categorical | | | 3 months ago | |
How many new schizophrenia treatments will be approved by the FDA by the end of 2025? | Categorical | | | 3 months ago | |
What will be the peak annual sales of Cobenfy by end of 2025? | Categorical | | | 3 months ago | |
Will Cobenfy receive a negative safety review from FDA by end of 2024? | Binary | | | 3 months ago | |
Region with highest initial sales of Cobenfy (KarXT) in 2024? | Categorical | | | 3 months ago | |
Major company announcing similar schizophrenia drug by end of 2025? | Categorical | | | 3 months ago | |
Primary side effect reported for Cobenfy (KarXT) by end of 2024? | Categorical | | | 3 months ago | |
What sales milestone will KarXT (Cobenfy) achieve within the first year of launch? | Categorical | | | 3 months ago | |
How many new schizophrenia treatments will be approved by the FDA by September 26, 2025? | Categorical | | | 3 months ago | |
Will KarXT (Cobenfy) achieve $500 million in sales within the first year of launch? | Binary | | | 3 months ago | |
What percentage of U.S. schizophrenia patients will be using KarXT (Cobenfy) by September 26, 2025? | Categorical | | | 3 months ago | |
